These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 34064798)

  • 1. Amplifications of Stemness Gene Loci-New Markers for the Determination of the Need for Neoadjuvant Chemotherapy for Patients with Breast Cancer. A Prospective Study.
    Litviakov NV; Ibragimova MK; Tsyganov MM; Kazantseva PV; Doroshenko AV; Garbukov EY; Frolova IG; Slonimskaya EM
    J Pers Med; 2021 May; 11(5):. PubMed ID: 34064798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amplifications of stemness genes and the capacity of breast tumors for metastasis.
    Litviakov N; Ibragimova M; Tsyganov M; Kazantseva P; Deryusheva I; Pevzner A; Doroshenko A; Garbukov E; Tarabanovskaya N; Slonimskaya E
    Oncotarget; 2020 May; 11(21):1988-2001. PubMed ID: 32523653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant Chemotherapy Induces the Appearance of New Copy Number Aberrations in Breast Tumor and is Associated with Metastasis.
    Litviakov NV; Ibragimova MK; Tsyganov MM; Doroshenko AV; Garbukov EY; Slonimskaya EM
    Curr Cancer Drug Targets; 2020; 20(9):681-688. PubMed ID: 31577208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole Transcriptome Analysis of Breast Cancer Tumors during Neoadjuvant Chemotherapy: Association with Hematogenous Metastasis.
    Ibragimova MK; Tsyganov MM; Litviakov NV
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deletions of multidrug resistance gene loci in breast cancer leads to the down-regulation of its expression and predict tumor response to neoadjuvant chemotherapy.
    Litviakov NV; Cherdyntseva NV; Tsyganov MM; Slonimskaya EM; Ibragimova MK; Kazantseva PV; Kzhyshkowska J; Choinzonov EL
    Oncotarget; 2016 Feb; 7(7):7829-41. PubMed ID: 26799285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Correlation of metastasis-free survival in patients with breast cancer and changes in the direction of expression of multidrug resistance genes during neoadjuvant chemotherapy].
    Litviakov NV; Garbukov EIu; Slonimskaia EM; Tsyganov MM; Denisov EV; Vtorushin SV; Khristenko KIu; Zav'ialova MV; Cherdyntseva NV
    Vopr Onkol; 2013; 59(3):334-40. PubMed ID: 23909034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic aberrations in carcinomas of the uterine corpus.
    Micci F; Teixeira MR; Haugom L; Kristensen G; Abeler VM; Heim S
    Genes Chromosomes Cancer; 2004 Jul; 40(3):229-46. PubMed ID: 15139002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prognostic analysis of neoadjuvant chemotherapy for locally advanced gastric cancer with propensity score matching method].
    Peng L; Yang W; Zhang Z; Zhi C; Zhou X; Liu H; Hua Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Oct; 21(10):1148-1153. PubMed ID: 30370514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcriptome of Breast Tumors With Different Amplification Status of the Long Arm of Chromosome 8.
    Ibragimova MK; Tsyganov MM; Pevzner AM; Litviakov NV
    Anticancer Res; 2021 Jan; 41(1):187-195. PubMed ID: 33419812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive and Prognostic Significance of mRNA Expression and DNA Copies Aberrations of
    Tsyganov MM; Ibragimova MK; Garbukov EY; Tsydenova IA; Gaptulbarova KA; Dolgasheva DS; Zdereva EA; Frolova AA; Slonimskaya EM; Litviakov NV
    Diagnostics (Basel); 2022 Feb; 12(2):. PubMed ID: 35204496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of M2 macrophage markers YKL-39 and CCL18 in breast cancer is associated with the effect of neoadjuvant chemotherapy.
    Litviakov N; Tsyganov M; Larionova I; Ibragimova M; Deryusheva I; Kazantseva P; Slonimskaya E; Frolova I; Choinzonov E; Cherdyntseva N; Kzhyshkowska J
    Cancer Chemother Pharmacol; 2018 Jul; 82(1):99-109. PubMed ID: 29728799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD44v9 as a poor prognostic factor of triple-negative breast cancer treated with neoadjuvant chemotherapy.
    Tokunaga E; Fujita A; Takizawa K; Baba K; Akiyoshi S; Nakamura Y; Ijichi H; Masuda T; Koga C; Tajiri W; Ohno S; Taguchi K; Ishida M
    Breast Cancer; 2019 Jan; 26(1):47-57. PubMed ID: 29971631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Follow-Up of Node-Negative Breast Cancer Patients Evaluated via Sentinel Node Biopsy After Neoadjuvant Chemotherapy.
    Nogi H; Uchida K; Mimoto R; Kamio M; Shioya H; Toriumi Y; Suzuki M; Nagasaki E; Kobayashi T; Takeyama H
    Clin Breast Cancer; 2017 Dec; 17(8):644-649. PubMed ID: 28601382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant Chemotherapy Use for Nonmetastatic Breast Cancer at Five Public South African Hospitals and Impact on Time to Initial Cancer Therapy.
    O'Neil DS; Nietz S; Buccimazza I; Singh U; Čačala S; Stopforth LW; Joffe M; Jacobson JS; Neugut AI; Crew KD; Ruff P; Cubasch H
    Oncologist; 2019 Jul; 24(7):933-944. PubMed ID: 30518615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study protocol of a multicenter phase III randomized controlled trial investigating the efficiency of the combination of neoadjuvant chemotherapy (NAC) and neoadjuvant laparoscopic intraperitoneal hyperthermic chemotherapy (NLHIPEC) followed by R0 gastrectomy with intraoperative HIPEC for advanced gastric cancer (AGC): dragon II trial.
    Beeharry MK; Ni ZT; Yang ZY; Zheng YN; Feng RH; Liu WT; Yan C; Yao XX; Li C; Yan M; Zhu ZG
    BMC Cancer; 2020 Mar; 20(1):224. PubMed ID: 32183736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Refining the indications for neoadjuvant chemotherapy for patients with HER2+ breast cancer: A single institution experience.
    Pomponio MK; Burkbauer L; Goldbach M; Nazarian SM; Xie F; Clark AS; Matro JM; Fox KR; Shulman LN; Keele LJ; Tchou J
    J Surg Oncol; 2020 Mar; 121(3):447-455. PubMed ID: 31919848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Factors in HER2-Positive Primary Breast Cancer Patients Treated Using Neoadjuvant Chemotherapy Plus Trastuzumab.
    Fujita N; Enomoto Y; Inakami K; Yanagisawa T; Iguchi C; Aono T; Nomura T; Yamamoto H; Kasugai T; Shiba E
    Oncology; 2020; 98(1):35-41. PubMed ID: 31574500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating HOTAIR expression predicts the clinical response to neoadjuvant chemotherapy in patients with breast cancer.
    Lu R; Zhang J; Zhang W; Huang Y; Wang N; Zhang Q; Qu S
    Cancer Biomark; 2018; 22(2):249-256. PubMed ID: 29630518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ki67 Changes Identify Worse Outcomes in Residual Breast Cancer Tumors After Neoadjuvant Chemotherapy.
    Cabrera-Galeana P; Muñoz-Montaño W; Lara-Medina F; Alvarado-Miranda A; Pérez-Sánchez V; Villarreal-Garza C; Quintero RM; Porras-Reyes F; Bargallo-Rocha E; Del Carmen I; Mohar A; Arrieta O
    Oncologist; 2018 Jun; 23(6):670-678. PubMed ID: 29490940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does the time from diagnostic biopsy to neoadjuvant chemotherapy affect the rate of pathologic complete response in stages I-III breast cancer?
    Le D; Eslami M; Li H; Hajjaj O; Chia S; Simmons C
    Curr Oncol; 2020 Jun; 27(3):e265-e270. PubMed ID: 32669932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.